Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience
Introduction: Specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of non-small cell lung cancer (NSCLC) patients that may be highly responsive to receptor inhibitor therapy. 18F-FDG PET/CT scans can map the glucose metabolism and treatment response of NSCLC. The...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Faculty of Medicine and Health Sciences, Universiti Putra Malaysia
2017
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/52558/ http://psasir.upm.edu.my/id/eprint/52558/1/2017050314422302_MJMHS_Jan_2017_-_0062_Mapping_18F.pdf |
| _version_ | 1848852137601138688 |
|---|---|
| author | Suppiah, Subapriya Ahmad Saad, Fathinul Fikri Mohad Azmi, Nur Hafizah Nordin, Abdul Jalil |
| author_facet | Suppiah, Subapriya Ahmad Saad, Fathinul Fikri Mohad Azmi, Nur Hafizah Nordin, Abdul Jalil |
| author_sort | Suppiah, Subapriya |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Introduction: Specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of non-small cell lung cancer (NSCLC) patients that may be highly responsive to receptor inhibitor therapy. 18F-FDG PET/CT scans can map the glucose metabolism and treatment response of NSCLC. Therefore, we aimed to assess the pattern of metabolic response and outcome of inoperable NSCLC treated with epidermal growth factor receptor (EGFR) inhibitors, using 18F-FDG PET/CT scan. Methods: A retrospective study of inoperable NSCLC patients on EGFR inhibitor treatment that were referred for wholebody18F-FDG PET/CT scans was conducted based on cases scanned from January 2011 to June 2014. Comparison was made among serial attenuation-corrected fused PET/CT images for all study patients throughout the course of their treatment. Comparison based on PERCIST criteria was categorized into 4 levels ie. complete response (CMR), partial response (PMR), stable disease (SMD), progressive metabolic disease (PMD). Results: Overall, there were 5 patients identified, mean age: 57.4 years old +/- 2.9 years; The median survival time from initiation of EGFR inhibitor treatment to death was 17 months. Two patients showed initial partial metabolic response (PMR), two had progressive metabolic disease (PMD) and one had complete metabolic response (CMR) after the initiation of treatment. The patient with initial CMR had relapse and PMD 5 months later. Majority of patients eventually succumbed to their illness. Conclusions: Wholebody18F-FDG PET/CT is able to assess metabolic treatment response of NSCLC towards EGFR inhibitor treatment. |
| first_indexed | 2025-11-15T10:33:18Z |
| format | Article |
| id | upm-52558 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T10:33:18Z |
| publishDate | 2017 |
| publisher | Faculty of Medicine and Health Sciences, Universiti Putra Malaysia |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-525582017-06-07T02:38:46Z http://psasir.upm.edu.my/id/eprint/52558/ Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience Suppiah, Subapriya Ahmad Saad, Fathinul Fikri Mohad Azmi, Nur Hafizah Nordin, Abdul Jalil Introduction: Specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of non-small cell lung cancer (NSCLC) patients that may be highly responsive to receptor inhibitor therapy. 18F-FDG PET/CT scans can map the glucose metabolism and treatment response of NSCLC. Therefore, we aimed to assess the pattern of metabolic response and outcome of inoperable NSCLC treated with epidermal growth factor receptor (EGFR) inhibitors, using 18F-FDG PET/CT scan. Methods: A retrospective study of inoperable NSCLC patients on EGFR inhibitor treatment that were referred for wholebody18F-FDG PET/CT scans was conducted based on cases scanned from January 2011 to June 2014. Comparison was made among serial attenuation-corrected fused PET/CT images for all study patients throughout the course of their treatment. Comparison based on PERCIST criteria was categorized into 4 levels ie. complete response (CMR), partial response (PMR), stable disease (SMD), progressive metabolic disease (PMD). Results: Overall, there were 5 patients identified, mean age: 57.4 years old +/- 2.9 years; The median survival time from initiation of EGFR inhibitor treatment to death was 17 months. Two patients showed initial partial metabolic response (PMR), two had progressive metabolic disease (PMD) and one had complete metabolic response (CMR) after the initiation of treatment. The patient with initial CMR had relapse and PMD 5 months later. Majority of patients eventually succumbed to their illness. Conclusions: Wholebody18F-FDG PET/CT is able to assess metabolic treatment response of NSCLC towards EGFR inhibitor treatment. Faculty of Medicine and Health Sciences, Universiti Putra Malaysia 2017 Article PeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/52558/1/2017050314422302_MJMHS_Jan_2017_-_0062_Mapping_18F.pdf Suppiah, Subapriya and Ahmad Saad, Fathinul Fikri and Mohad Azmi, Nur Hafizah and Nordin, Abdul Jalil (2017) Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience. Malaysian Journal of Medicine and Health Sciences, 13 (1). pp. 9-15. ISSN 1675-8544 http://www.medic.upm.edu.my/upload/dokumen/2017050314422302_MJMHS_Jan_2017_-_0062_Mapping_18F.pdf |
| spellingShingle | Suppiah, Subapriya Ahmad Saad, Fathinul Fikri Mohad Azmi, Nur Hafizah Nordin, Abdul Jalil Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience |
| title | Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience |
| title_full | Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience |
| title_fullStr | Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience |
| title_full_unstemmed | Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience |
| title_short | Mapping 18F-fluorodeoxyglucose metabolism using PET/CT for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience |
| title_sort | mapping 18f-fluorodeoxyglucose metabolism using pet/ct for the assessment of treatment response in non-small cell lung cancer patients undergoing epidermal growth factor receptor inhibitor treatment: a single-centre experience |
| url | http://psasir.upm.edu.my/id/eprint/52558/ http://psasir.upm.edu.my/id/eprint/52558/ http://psasir.upm.edu.my/id/eprint/52558/1/2017050314422302_MJMHS_Jan_2017_-_0062_Mapping_18F.pdf |